Drug researcher up to ten retractions

A pharmaceutical researcher has received his tenth retraction. The reason, once again: duplicating his previous work.

Giuseppe Derosa, based at the University of Pavia in Italy, lost a 2011 paper this month after journal editors identified “substantial duplication of an earlier published paper.” According to the notice, the authors failed to cite the previous work and to disclose that the manuscript had been published or was under consideration elsewhere.

Derosa has a habit of reusing clinical trial data in multiple papers. He received his first four retractions in 2015 for publishing the same clinical trial results six times—two of those papers were retracted over the summer and two more several months later. By 2016, a fifth from the bunch was retracted (one of the six still stands). Derosa received another retraction, citing duplication (which we covered here and which was not related to the six clinical trials).

Continue reading Drug researcher up to ten retractions

BMJ journal yanks paper on cancer screening in India for fear of legal action

BMJ Global Health has pulled a paper that criticized U.S. research of the effects of cervical cancer screening in India over defamation concerns.

That’s not what the notice on the paper says, however — at the moment, it just reads:

This article has been withdrawn.

However, forwarded email correspondence between the first author and an associate publisher reveals the journal published the paper and planned a press release, then realized it should be reviewed by a legal adviser. When first author Eric J. Suba at Kaiser Permanente San Francisco Medical Center inquired about the status of the paper and any potential press release, he was told the journal could no longer publish it, out of concern they would be taken to court.

Suba told us that, when he learned the paper would be pulled:

Continue reading BMJ journal yanks paper on cancer screening in India for fear of legal action

It’s not just whistleblowers who deserve protection during misconduct investigations, say researchers

Sven Hendrix
Lex Bouter

In 2010, the former PhD supervisor of Sven Hendrix, a neuroanatomist at Hasselt University in Belgium, was accused of misconduct. Although the allegations were eventually dropped, the experience was emotionally and professionally draining – and Hendrix wanted the research community to know about it. In 2015, he shared his story at a conference in Rotterdam; in the audience was Lex Bouter at Vrije Universiteit in Amsterdam, who works on research integrity (and is co-chair of this year’s World Conference on Research Integrity [WCRI], happening now). Bouter invited Hendrix to write a paper with him. This month, Accountability in Research published “Both Whistle Blowers and the Scientists They Accuse are Vulnerable and Deserve Protection,” an abstract of which is being presented today at the WCRI. We spoke with Hendrix and Bouter about their paper.

Retraction Watch: The title of your paper kind of says it all. Can you say more about what prompted you to write it?

Continue reading It’s not just whistleblowers who deserve protection during misconduct investigations, say researchers

Weekend reads: The editor who’s a dog; the fake author; a monument to peer review

The week at Retraction Watch featured the retraction of a much-discussed paper on using blockchain to prevent scientific misconduct, and a researcher who lost nine studies at once from a single journal. Here’s what was happening elsewhere: Continue reading Weekend reads: The editor who’s a dog; the fake author; a monument to peer review

“There is an injustice in this article”

The editors of a plant biology journal have retracted a 2007 paper because of “an injustice.”

According to the notice, the editors of Cytologia found evidence of “apparent figure manipulation,” and decided to retract the paper.

This marks the 10th retraction for plant biologist Dibyendu Talukdar.

Talukdar, who is first and corresponding author on the 2007 paper and listed at the University of Calcutta in West Bengal, India, received his first retraction last July, which also cited suspected figure manipulation. Earlier this year, Talukdar received eight more retractions in seven different journals, all describing concerns over potential image duplication and manipulation.

Here’s the most recent retraction notice in Cytologia: Continue reading “There is an injustice in this article”

Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

A neurochemistry journal has retracted a paper from a group in China over a duplicated image.

According to the notice, the authors used the same image in the two papers to represent different experimental conditions. The only distinguishing feature between the images: “apparent brightness changes.”

The authors defended their actions, explaining that the research published in Journal of Neurochemistry “sequentially builds” on their previous study in Journal of Neuroinflammation, which they mention in the 2015 paper’s discussion. In the notice, the authors were quoted saying:  Continue reading Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

Would-be Johns Hopkins whistleblower loses appeal in case involving Nature retraction

A former researcher at Johns Hopkins who voiced concerns about a now-retracted paper in Nature has lost another bid for whistleblower protection.

Daniel Yuan, a longtime statistician for former Hopkins yeast geneticist Jef Boeke, was dismissed in 2011, after he’d spent years raising concerns about research coming out of the lab. Yuan’s criticisms, which continued after he stopped working for Boeke, peaked in 2012 after Boeke and former labmate Yu-li Lin published a paper in Nature. Later that year, Lin was found dead in his lab, a suspected suicide. In 2013, the paper was retracted, citing an inability to reproduce the main conclusions. 

Since 2013, Yuan has pursued a wrongful termination lawsuit, claiming that federal regulations surrounding scientific misconduct afforded him protection from retaliation.

In late March, Maryland’s highest court ruled against Yuan, saying that those misconduct regulations are “too vague” to offer cover to employees claiming whistleblower protection. According to lawyers we consulted, the decision could make it harder for would-be whistleblowers to fight retaliation, while also giving institutions more leeway to handle these issues on their own.

Continue reading Would-be Johns Hopkins whistleblower loses appeal in case involving Nature retraction

Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

On April 27, the Journal of Biological Chemistry (JBC) retracted nine papers by a researcher based in Israel, including some dating back to 2000.

The reason: Image manipulation.

Michal Neeman, vice president of The Weizmann Institute of Science, told us that the researcher, Rony Seger, is under investigation following an allegation of misconduct affecting papers in multiple journals.

So far, we’ve found 11 retractions for papers by Seger, a molecular biologist. In the notices, the authors state they have “full confidence” in the findings, and in many instances have replicated the work.

According to Neeman:

Continue reading Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

Publisher blames bad choice of reviewer for publication of hoax paper on penis as “social construct” 

Less than a week after publishing a much-discussed hoax paper, a scholarly publisher has acknowledged that it had chosen reviewers for the paper whose “expertise did not fully align with this subject matter.”

The subject matter: that the penis should not be considered an anatomical organ, but more as a concept – “a gender-performative, highly fluid social construct.” Upon publication, the authors immediately admitted the paper was a prank, arguing that its publication illustrates a lack of intellectual and scientific rigor in some social sciences, especially gender studies. But others have questioned whether it really demonstrates that at all.

In response to the revelation of the hoax, Taylor & Francis associate editorial director Emma Greenword published a statement about the process that led to this entanglement: Continue reading Publisher blames bad choice of reviewer for publication of hoax paper on penis as “social construct” 

Authors retract much-debated blockchain paper from F1000

The authors of a popular — and heavily debated — F1000Research paper proposing a method to prevent scientific misconduct have decided to retract it.

The paper was initially criticized for allegedly plagiarizing from a graduate student’s blog — and revised to try to “rectify the overlap.” But according to F1000, it is now being retracted after an additional expert identified problems with the methodology.

Today, F1000 added this editorial note to the paper:

Continue reading Authors retract much-debated blockchain paper from F1000